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Validation of the revised IPSS at transplant in patients with
myelodysplastic syndrome/transformed acute myelogenous
leukemia receiving allogeneic stem cell transplantation: a
retrospective analysis of the EBMT chronic malignancies
working party
C Scheid1, L de Wreede2,3, A van Biezen2, C Koenecke4, G Göhring5, L Volin6, J Maertens7, J Finke8, J Passweg9, D Beelen10,
JJ Cornelissen11, M Itälä-Remes12, P Chevallier13, N Russell14, E Petersen15, N Milpied16, C Richard Espiga17, A Peniket18, J Sierra19,
G Mufti20, C Crawley21, JH Veelken22, P Ljungman23, JY Cahn24, EP Alessandrino25, T de Witte26, M Robin27 and N Kröger28
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic
syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a
retrospective analysis of the EBMT database. A total of 579 patients had sufﬁcient information available to calculate IPSS-R at
transplant. Median overall survival (OS) from transplant was signiﬁcantly different according to IPSS-R: very low 23.6 months, low
55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (Po0.001). In a multivariate Cox model the
following parameters were signiﬁcant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival
also showed signiﬁcant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high
7.9 months, very high 5.5 months (Po0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity
conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We
conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both
disease evolution and response to prior treatment before transplant.
Bone Marrow Transplantation (2017) 52, 1519–1525; doi:10.1038/bmt.2017.171; published online 11 September 2017
INTRODUCTION
Myelodysplastic syndrome (MDS) is a disease with a highly variable
course ranging from stable cytopenia to rapid progression to acute
leukemia. Since the management of MDS is largely dependent on
the anticipated prognosis of each patient, multiple scoring systems
have been developed to predict prognosis using disease related
parameters at diagnosis. The International Prognostic Scoring
System (IPSS) has been revised to include a more detailed risk
stratiﬁcation of genetic changes in MDS.1 The revised IPSS (IPSS-R)
allocates patients into ﬁve different risk categories with a predicted
median overall survival (OS) from diagnosis from 0.8 years for the
very high risk group to 8.8 years for very low risk disease.
The IPSS-R at transplant has been used to predict survival after
allogeneic stem cell transplantation.2 However, nearly half of the
patients received additional therapy before undergoing trans-
plantation and in these cases IPSS-R was assessed prior to this
therapy instead of prior to allografting. A recent study from Korea3
analyzed IPSS-R before and after hypomethylating therapy prior to
allogeneic transplantation and found the assessment before
transplant to give a better prediction of OS. Several groups have
proposed new scoring systems to predict transplant outcome in
MDS.3,4 However the parameters of these scores are largely
overlapping with the constituents of the IPSS-R and the
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improvement in predictive power was only modest compared to
the IPSS-R.4
Since the IPSS-R is well established and easily available, we
sought to validate it in a large cohort of patients with MDS or
transformed AML from the EBMT database. Although the IPSS-R
was originally developed for untreated MDS patients only, we
included also patients with prior therapy before allografting as
well as patients with 430% blasts to reﬂect the full spectrum of
patients with MDS and MDS transformed to AML presenting for
allogeneic transplantation.
PATIENTS AND METHODS
A retrospective analysis of the EBMT database was performed. All ﬁrst
allogeneic transplants performed for the diagnosis MDS or transformed
AML evolving from MDS in the time period 1982–2010 were selected.
Pediatric patients and transplants with cord blood or from mismatched
donors were excluded. Only patients with available information on bone
marrow blast count, cytogenetics, hemoglobin, platelets and leukocytes at
transplant were used to calculate IPSS-R at transplant according to
Greenberg et al.1 Since IPSS-R is among others based on the ANC which
was not available in the database, the ANC was assumed to be 50% of the
leukocyte count. The genetic information was scored according to
Schanz et al.5 by a geneticist. Patients with incomplete or inconclusive
genetic data were excluded.
Proportions were compared by the χ2 test. Outcomes of primary interest
were OS and relapse-free survival (RFS), deﬁned as survival in the absence
of a new relapse or progression after transplantation. Univariate survival
analyses were performed by the Kaplan–Meier method; outcomes of
groups were compared with the log-rank test. Cumulative incidences of
relapse (CIR) and non-relapse mortality (NRM) were calculated as each
other’s competing risks. Differences in CIR and NRM between groups were
compared by the Gray test. All outcomes were measured from time of
transplantation onward and were artiﬁcially censored at 5 years after
transplantation.
Table 1. Patient characteristics
IPSS-R category Very low Low intermediate High Very high Total P
n=16 n= 153 n=141 n= 147 n= 122 N= 579
Age (yr) (n= 579) 0.34
18–40 3 (18.8%) 40 (26.1%) 27 (19.1%) 43 (29.3%) 27 (22.1%) 140 (24.2%)
41–50 3 (18.8%) 36 (23.5%) 33 (23.4%) 28 (19.0%) 19 (15.6%) 119 (20.6%)
51–60 5 (31.3%) 48 (31.4%) 55 (39.0%) 40 (27.2%) 45 (36.9%) 193 (33.3%)
460 5 (31.3%) 29 (19.0%) 26 (18.4%) 36 (24.5%) 31 (25.4%) 127 (21.9%)
Sex (n = 579) 0.28
Male 6 (37.5%) 81 (52.9%) 87 (61.7%) 79 (53.3%) 65 (53.3%) 318 (54.9%)
Female 10 (62.5%) 72 (47.1%) 54 (38.3%) 68 (46.3%) 57 (46.7%) 261 (45.1%)
Donor (n = 579) 0.47
Related 12 (75.0%) 93 (60.8%) 82 (58.2%) 84 (57.1%) 65 (53.3%) 336 (58.0%)
Unrelated 4 (25.0%) 60 (39.2%) 59 (41.8%) 63 (42.9%) 57 (46.7%) 243 (42.0%)
Graft source (n= 579) 0.76
PB 12 (75.0%) 111 (72.5%) 100 (70.9%) 98 (66.7%) 82 (67.2%) 403 (69.6%)
BM 4 (25.0%) 42 (27.5%) 41 (29.1%) 49 (33.3%) 40 (32.8%) 176 (30.4%)
Sex match (n= 579) 0.25
Female donor to male patient 1 (6.3%) 21 (13.7%) 31 (22.0%) 29 (19.7%) 22 (18.0%) 104 (18.0%)
Other combinations 15 (93.8%) 132 (86.3%) 110 (78.0%) 118 (80.3%) 100 (82.0%) 475 (82.0%)
Conditioning (n= 579) 0.89
Standard 10 (62,5%) 89 (58.2%) 87 (61.7%) 87 (59.2%) 76 (62.3%) 349 (60.3%)
Reduced 6 (37.5%) 64 (41.8%) 54 (38.3%) 59 (40.1%) 46 (37.7%) 229 (39.6%)
CMV status (n= 579) 0.28
Rec− /don− 6 (37.5%) 46 (30.1%) 46 (32.6%) 33 (22.4%) 21 (17.2%) 152 (26.3%)
Rec− /don+ 1 (6.3%) 11 (7.2%) 13 (9.2%) 19 (12.9%) 15 (12.3%) 59 (10.2%)
Rec+/don− 2 (12.5%) 34 (22.2%) 31 (22.0%) 35 (23.8%) 30 (24.6%) 132 (22.8%)
Rec+/don+ 6 (37.5%) 52 (34.0%) 45 (31.9%) 52 (35.4%) 42 (34.4%) 197 (34.0%)
Interval Dx-Tx (n= 579) 0.41
o6 mo 8 (50.0%) 58 (37.9%) 61 (42.3%) 61 (41.5%) 44 (26.1%) 232 (40.1%)
6–12 mo 5 (31.3%) 81 (29.6%) 59 (41.8%) 65 (44.2%) 64 (52.5%) 274 (47.3%)
412 mo 3 (18.8%) 14 (9.2%) 21 (14.9%) 21 (14.3%) 14 (11.5%) 73 (12.6%)
Prior treatment (n= 572) 0.004
No 3 (18.8%) 37 (24.5%) 49 (35.0%) 62 (43.1%) 58 (47.9%) 209 (36.5%)
Yes 13 (81.3%) 114 (75.5%) 91 (65.0%) 82 (56.9%) 63 (52.1%) 363 (63.4%)
WHO class (n= 546) o0.001
RA/RARS/del5q RCDM-RS 3 (20.0%) 34 (23.6%) 28 (21.2%) 20 (13.9%) 4 (3.4%) 89 (16.1%)
CMML – 9 (6.3%) 10 (7.6%) 5 (3.5%) 2 (1.7%) 26 (4.7%)
RAEB 1,2 2 (13.3%) 46 (31.9%) 53 (40.2%) 56 (38.9%) 49 (41.5%) 206 (37.3%)
sAML 10 (66.7%) 55 (38.2%) 41 (31.1%) 63 (43.8%) 63 (53.4%) 232 (42.0%)
Abbreviations: BM=bone marrow; CMML= chronic mylelomonocytic leukemia; IPSS-R= revised International Prognostic Scoring System; mo=month;
RAEB= refractory anemia with excess of blasts; yr= year.
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Multivariate analyses were done by Cox proportional (cause-speciﬁc)
hazards regression models. Two series of models were ﬁtted. In the ﬁrst,
the differential impact of the components of the IPSS-R was assessed to
see if the points associated with them in the score adequately reﬂect this
impact. In the second series, it was investigated whether IPSS-R kept its
impact in the presence of classical predictors. These predictors were
selected on the basis of clinical and statistical considerations in models
without IPSS-R. For each outcome, a new backward stepwise selection
procedure was then performed in a model containing IPSS-R and the
selected classical predictors. All analyses were performed in SPSS (version
23) and R 3.0.2, with library ‘cmprsk’.
RESULTS
A total of 3276 allogeneic transplants in patients with MDS or MDS
transformed to AML performed between 1982 and 2010 were
found in the database. A total of 579 patients had sufﬁcient
information to calculate IPSS-R at transplant, yielding a very low
risk in 16 (2.8%), low risk in 152 (26.3%), intermediate risk in 141
(24.4%), high risk in 147 (25.4%) and very high risk in 123 (21.2%)
of the cases. Most other parameters regarding patient and
transplant characteristics were well balanced between the IPSS-R
subgroups and are summarized in Table 1. About half of the
patients were male, 22% were older than 60 years, about a third
had bone marrow as graft source and 40% received a
reduced-intensity conditioning. Most patients were transplanted
within the ﬁrst year after diagnosis. There were no signiﬁcant
differences in the above characteristics between the IPSS-R
subgroups. The majority of patients had received MDS-treatment
before undergoing allogeneic stem cell transplantation and this
proportion was signiﬁcantly higher in the lower risk categories,
ranging from 81.2% in very low risk to 50.8% in very high risk
(P= 0.005).
Overall survival
Estimation of OS at 2 years according to IPSS-R at transplant
(Figure 1) was 47.4% in the very low risk group, 60.5% with low
risk, 46.9% with intermediate risk, 43,5% with high risk and 27.7%
in the very high risk group (Po0.001). In a univariate Cox
model with the very high risk group as reference, all IPSS-R
categories except the very low risk group were signiﬁcant factors
for OS with hazard ratios of 0.518 for very low risk, 0.444 for low
risk, 0.607 for intermediate risk and 0.711 for high risk (Table 2a).
When analyzing patients with and without prior treatment
separately, IPSS-R was still a signiﬁcant factor for OS in
treatment-naïve (P= 0.025) and in previously treated patients
(Po0.001).
To assess the contribution of the different components of IPSS-
R on transplant outcome, we performed a multivariate Cox model
using the categories for genetic risk, blast count, hemoglobin,
platelets and neutrophil count as parameters separately. As shown
in Table 2b cytogenetic risk group (Po0.001) and bone marrow
blasts (P= 0.004) were signiﬁcant predictors for OS while
cytopenia was not.
To investigate the IPSS-R in relation to other known risk
factors for transplant outcome (age, donor type, graft source,
conditioning intensity, CMV-status, female donor for male
patients, interval between diagnosis and transplant, year of
transplant) and in particular to disease status and previous
treatment, both of which were found to be unevenly distributed
within the IPSS-R risk categories, we performed a multivariate
Cox analysis with a selection procedure. In this analysis the
following parameters were found to be signiﬁcantly
associated with OS: graft source (PB vs BM, HR 0.747, P= 0.02),
age (P= 0.041), prior treatment (hazard ratio (HR) 1.695,
Po0.001, and IPSS-R (Po0.001) (Table 3, complete Cox model
shown in Supplementary Table 1). The size of the impact of IPSS-R
was almost equal in the models with and without other risk
factors.
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Figure 1. OS according to IPSS-R at transplant.
Table 2. Cox model for OS
Hazard
ratio
Lower limit
95%CI
Upper limit
95% CI
P-value
a. Univariate Cox model for IPSS-R
IPSS-R o0.001
Very low 0.518 0.251 1.068 0.075
Low 0.444 0.322 0.612 o0.001
Intermediate 0.607 0.448 0.822 0.001
High 0.711 0.529 0.956 0.024
Very high 1
b. Multivariate Cox model for the components of IPSS-R
Genetic risk groupa o0.001
0 1
1 3.933 0.958 16.148 0.057
2 4.013 0.986 16.339 0.052
3 4.607 1.118 18.980 0.034
4 9.614 2.292 40.332 0.002
Blasts 0.004
o2% 1
2–5% 1.025 0.744 1.412 0.881
5–10% 1.311 0.968 1.775 0.080
410% 1.697 1.250 2.302 0.001
Hemoglobin x109/l 0.912
410 g/dL 1
8–10 g/dL 1.045 0.806 1.356 0.738
o8 g/dL 0.986 0.701 1.386 0.934
Platelets x109/l 0.721
4100 1
50–100 1.069 0.792 1.444 0.663
o50 1.120 0.850 1.476 0.420
ANC x109/l
40.8 1
o0.8 1.298 0.996 1.690 0.053
Abbreviations: IPSS-R= revised International Prognostic Scoring System;
OS=overall survival. aAccording to Schanz et al.5
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Relapse-free survival
IPSS-R predicted RFS at 24 months after transplant (Figure 2) with
47.7, 52.0, 40.9, 34.2 and 23.7% in the very low, low, intermediate,
high and very high risk group, respectively (Po0.001). In a
univariate Cox model all IPSS-R categories except very low risk
were found to be signiﬁcant factors for RFS (Table 4a). Regarding
the effect of the individual components of the IPSS-R on RFS,
neutrophil count was found to be a signiﬁcant predictor in
addition to cytogenetic risk group and bone marrow blasts, while
hemoglobin and platelets were not signiﬁcant (Table 4b).
In a multivariate Cox model for RFS including the above
mentioned disease- and transplant-related risk factors, condition-
ing intensity (reduced versus myeloablative, HR 1.289, P= 0.027),
prior treatment (HR 1.654, Po0.001), graft source (PB vs BM, HR
0.738, P= 0.011) and IPSS-R (Po0.001) were found to be
signiﬁcant covariates after backward selection (Table 5, complete
Cox model shown in Supplementary Table 2).
NRM and relapse incidence
There was a trend for a higher cumulative relapse incidence (RI) in
the very high risk group amounting to 43.8% at 24 months,
whereas the RI at 24 months ranged from 26.7 to 34.2% in the
other risk categories (Figure 3, P= 0.20). The cumulative incidence
of non-relapse mortality was 27.5% at 24 months and showed no
signiﬁcant differences in relation to IPSS-R at transplant in a
univariate comparison (Figure 4).
To further explore in what way the IPSS-R inﬂuences transplant
outcomes, we analyzed the risk factors predicting OS and RFS in
multivariate Cox models for the cause-speciﬁc hazards of
relapse and NRM. IPSS-R (Po0.001) and prior treatment (HR
2.62, 95% CI 1.87–3.68, Po0.001) were found to predict
relapse risk whereas IPSS-R (P= 0.041) and graft source (PB vs
BM, HR 0.53, 95% CI 0.37–0.75, Po0.001) were signiﬁcant factors
for NRM.
DISCUSSION
Predicting the outcome after allogeneic transplantation remains a
challenge for transplant physicians, in particular for diseases with
a variable natural course. While parameters related to the
transplant complications like age or donor type have been used
widely and are considered in prognostic scores such as the EBMT
score, the risks conferred by the underlying—and eventually
evolving—disease are more difﬁcult to assess. Several prognostic
scores for MDS predict OS from diagnosis, at latest the IPSS-R,1
which incorporates the bone marrow blast counts, ﬁve genetic risk
categories and cytopenias of the three lineages.
World Health Organisation (WHO) disease stage has previously
been found to be predictive of transplant outcome.6 Our results
show that WHO disease stage is no longer signiﬁcant for OS or RFS
if IPSS-R is assessed simultaneously, probably because of a high
correlation between the variables since both are strongly related
to the blast counts. IPSS risk score—assessed at diagnosis—is
known to predict outcome of allogeneic transplantation.7–9 Since
often some time evolves between diagnosis and transplantation
and MDS-directed therapy might have been applied in between,
assessing IPSS-R at diagnosis may not truly reﬂect the disease
status at transplant.
Several attempts have been made to use disease risk scores
during the course of the disease to predict transplant outcome:
Alessandrino et al.6 have studied 365 patients with AML or MDS
from the Italian registry and analyzed both WHO stage and WHO-
based prognostic scoring system (WPSS) score at transplant or
before induction chemotherapy in those patients receiving prior
therapy. Both WHO stage and WPSS were strongly correlated with
OS and relapse incidence in univariate and multivariate models.
However since both factors were recorded before a given
induction chemotherapy, response to this therapy did not enter
in the risk score and had to be analyzed as a separate covariate.
The achievement of CR after induction before transplantation was
a signiﬁcant factor for OS and relapse incidence in patients with
AML, but not with RAEB I or II. It therefore appears advantageous
to assess the risk score directly before transplantation to integrate
both disease risk and response to prior treatment into on single
risk score. Lee et al.9 have reported on transplant outcome in
relation to IPSS risk as assessed at transplant in a small single
center study including 68 patients. IPSS at transplant was
predictive of OS and EFS and eliminated WHO disease stage and
IPSS at diagnosis when entered into a multivariate model.
However the IPSS score has been generally challenged to
Table 3. Multivariate Cox model for OS
Hazard
ratio
Lower limit
95% CI
Upper limit
95% CI
P-value
Graft source
BM (reference) 1
PBSC 0.747 0.584 0.955 0.020
Prior treatment
No (reference) 1
Yes 1.695 1.325 2.168 o0.001
Age category 0.041
18–40 years
(reference)
1
40–50 years 1.007 0.712 1.425 0.967
50–60 years 1.153 0.845 1.574 0.370
460 years 1.537 1.097 2.152 0.012
IPSS-R o0.001
Very low 0.454 0.219 0.942 0.034
Low 0.395 0.283 0.552 o0.001
Intermediate 0.595 0.435 0.813 0.001
High 0.689 0.509 0.933 0.016
Very high
(reference)
1
Abbreviations: IPSS-R= revised International Prognostic Scoring System;
OS=overall survival.
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Figure 2. RFS according to IPSS-R at transplant.
Validation of the IPSS-R at transplant in patients with MDS
C Scheid et al
1522
Bone Marrow Transplantation (2017) 1519 – 1525
underestimate the risk of genetic changes and a novel genetic risk
score to estimate survival from diagnosis in MDS patients has
been published.5 This genetic ﬁve-group risk score has been
recently been tested in patients undergoing allogeneic
transplantation.10 The French SFGM-TC group analyzed the ﬁve
group genetic score at diagnosis with regard to its prognostic
relevance for allogeneic transplantation. In multivariate analysis
the genetic score predicted OS after transplant with blast count at
transplant and TBI-containing conditioning as signiﬁcant covari-
ates. Progression after prior therapy was also a negative factor but
did not reach statistical signiﬁcance. Using the same genetic risk
score but assessed at transplant Deeg et al.11 found signiﬁcant
hazard ratios for OS for the poor and very poor risk group with no
signiﬁcant difference for the very good and intermediate risk
groups in univariate analysis using the good risk group as
reference. Besides genetic risk group, a large number of other
parameters were found to predict OS in a multivariate model such
as age, year of transplant, conditioning regimen, WHO disease
stage, platelet count, donor type and antecedent disease. Thus the
ﬁve group genetic risk score identiﬁed a subgroup of patients with
an overwhelmingly high risk of relapse and mortality after
transplant. Similar to the ﬁndings by Deeg et al.12, our
group found the ﬁve group cytogenetic risk score to be superior
for predicting transplant outcome than the categorization in the
IPSS score. WHO disease category and remission status were
additional prognostic factors for OS and RFS in multivariate
models.
The Italian group2 has published a study investigating the role
of IPSS-R to predict transplant outcome in 519 patients with MDS
and oligoblastic AML and could show that the IPSS-R was
prognostic for OS and relapse incidence. However, the risk
assessment was performed at transplant only for patients
receiving an upfront transplantation. For patients undergoing
prior induction therapy the score was analyzed before induction
and response to this therapy had to be captured in a separate
variable. Both IPSS-R and response to induction were found to be
independent factors for OS and relapse incidence. Thus assessing
the IPSS-R before the start of induction therapy does not allow
capture of multiple risk factors in a single risk score. In fact a small
retrospective study from two Korean transplant centers3 in 201
patients of whom 115 received hypomethylating therapy prior to
transplant, IPSS-R assessed at transplant was a better predictor of
transplant outcome than IPSS-R before the start of hypomethylat-
ing treatment.
In our retrospective registry-based analysis including 579
patients, we conﬁrm the validity of assessing the IPSS-R score
immediately before transplant irrespective of a prior treatment
and accounting for a number of known factors related to the
outcome of allogeneic transplantation. Similar to the study by
Yahng et al.3 we found a high proportion of patients being
‘downstaged’ before transplant, starting with AML evolved from
MDS and presenting for transplant with a low risk IPSS-R after
therapy. With our approach we could limit the prognostic
factors for OS in a multivariate model to IPSS-R, age, graft
source and prior treatment. For RFS besides IPSS-R we found
graft source, conditioning intensity and prior treatment to be
predictive. We therefore propose to use IPSS-R as easy
and comprehensive score to capture a number of pre-transplant
risk factors in a single, widely used scoring system for MDS
patients.
Still our study has some limitations to consider: only very few
patients fell in the very low risk category and therefor the results
for this subgroup have to be taken with caution. In fact OS and
RFS appeared to be inferior to the low risk group. This may partly
be explained by the high level of uncertainty when analyzing
survival data in a cohort of only 16 patients. In addition this
Table 5. Multivariate Cox model for RFS
Hazard
ratio
Lower limit
95% CI
Upper limit
95% CI
P-value
Conditioning
Myeloablative
(reference)
1
reduced intensity 1.289 1.029 1.615 0.027
Prior treatment
No (reference) 1
Yes 1.654 1.312 2.085 o0.001
Graft source
BM (reference) 1
PBSC 0.738 0.584 0.934 0.011
IPSS-R o0.001
Very low 0.478 0.239 0.953 0.036
Low 0.430 0.315 0.586 o0.001
Intermediate 0.597 0.443 0.806 0.001
High 0.697 0.520 0.933 0.015
Very high
(reference)
1
Abbreviations: IPSS-R= revised International Prognostic Scoring System;
RFS= relapse-free survival.
Table 4. Cox model for RFS
Hazard
ratio
Lower limit
95%CI
Upper limit
95% CI
P-value
a. Univariate Cox model for IPSS-R
IPSS-R o0.001
Very low 0.552 0.278 1.095 0.089
Low 0.501 0.371 0.676 o0.001
Intermediate 0.625 0.467 0.838 0.002
High 0.739 0.555 0.985 0.039
Very high 1
b. Multivariate Cox model for the components of IPSS-R
Genetic risk groupa o0.001
0 1
1 1.692 0.678 4.225 0.260
2 1.731 0.702 4.266 0.233
3 2.089 0.835 5.230 0.115
4 4.177 1.624 10.747 0.003
Blasts 0.005
o2% 1
2–5% 1.056 0.781 1.428 0.724
5–10% 1.341 1.009 1.783 0.043
410% 1.655 1.232 2.224 0.001
Hemoglobin 0.908
410 g/dL 1
8–10 g/dL 1.053 0.822 1.348 0.683
o8 g/dL 1.008 0.729 1.393 0.962
Platelets 0.988
4100 1
50–100 1.008 0.760 1.337 0.955
o50 0.987 0.760 1.281 0.921
ANC
40.8 1
o0.8 1.316 1.023 1.694 0.033
Abbreviations: IPSS-R= revised International Prognostic Scoring System;
RFS= relapse-free survival. aAccording to Schanz et al.5.
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subgroup showed the highest rate of prior AML (66.7%) and prior
treatment (81.3%) and may biologically be more comparable to
AML in complete remission than MDS. However a much larger
patient cohort would be needed to further elucidate this point.
The neutrophil count required to calculate IPSS-R was not
available and had to be estimated based on the leukocyte count.
However, given the very limited weight of the neutrophils in the
IPSS-R score, we do not think this had an inﬂuence on our
ﬁndings. Of note in the analysis by Della Porta2 the neutrophil
count did not have any prognostic implications. Furthermore the
genetic information contained in the EBMT database is far from
being complete and a large number of patients had to be
excluded due to lack of data. Although we cannot exclude a
selection bias when analyzing a few hundred cases out of
thousands, the overall and relapse-free survival of the initial cohort
was comparable to the subgroup with sufﬁcient data to
calculate IPSS-R. And ﬁnally the role of induction therapy
before transplant needs to be considered very carefully.
While in our analysis prior treatment was a negative prognostic
factor this does by no means prove the futility of
induction therapy. It rather suggests that a given IPSS-R score
may have a worse prognostic implication if it reﬂects the result of
a prior treatment attempt (and thus potentially resistant disease)
rather than spontaneous disease evolution. Conversely a
high number of patients with transformed AML presented at
transplant with a low IPSS-R risk after effective therapy and may
thus have improved their prognosis after transplant. The beneﬁt of
induction treatment before allogeneic transplantation remains a
controversial issue13 and can only be assessed by prospective
studies.
In summary, we have shown the IPSS-R score at transplant
includes many of disease- and therapy-related factors in one score
and may help to identify patients with a favorable transplant
outcome and those needing additional pre- or post-transplant
interventions to improve prognosis. In the future the incorpora-
tion of molecular alterations such as TP53, RUNX1 or ASXL114 in
the pre-transplant assessment may further improve the prediction
of transplant outcome in MDS.
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Figure 4. Cumulative incidence of non-relapse mortality according
to IPSS-R at transplant.
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Figure 3. Cumulative incidence of relapse according to IPSS-R
at transplant.
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